Author: admin

DelveInsight’s, “Glioma Competitive landscape, 2025,” report provides comprehensive insights about 200+ companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the full insights into the evolving Glioma Pipeline and discover which companies are leading the innovation race @ Glioma Competitive Landscape Report

Key Takeaways from the Glioma Competitive Landscape Report

• On 19 August 2025, Nuvation Bio Inc. announced a study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.
• DelveInsight’s Glioma Competitive Landsapereport depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies for Glioma treatment.
• The leading Glioma Companies such as Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac, and others.
• Promising Glioma Therapies such as DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide, and others.

Unlock detailed analysis of the Glioma Competitive Landscape 2025 and identify key growth opportunities @ Glioma Research and Development Report

Glioma Marketed Therapies

• Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, the innovative science and digital technologies to create transformative treatments in areas of great medical need and find new medicines, the company consistently rank among the world’s top companies investing in research and development.

• Tafinlar + Mekinist

The combination of Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition research and patients reached, helps in slowing tumor growth by blocking signals associated with the BRAF and MEK kinases that are implicated in the growth of various types of cancer. Tafinlar + Mekinist has been studied in more than 6,000 BRAF-positive patients in more than 20 ongoing and completed trials, including in pediatric patients 1 year of age and older, and has been prescribed to more than 200,000 patients worldwide.

• NX Development Corp.

NX Development Corp. (NXDC) is a life sciences company based in Lexington, KY dedicated to the development of ALA HCl for tumor visualization. NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; “”PHN””). PHN is the licensor of GleolanTM (aminolevulinic acid HCl [ALA HCl]) to NXDC. The companies share an eight-year working relationship and are wholly-owned by SBI Holdings Inc. (Tokyo, Japan).

• GLEOLAN

GLEOLAN (ALA HCl) is an FDA-approved optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. Exogenous administration of ALA HCl leads to accumulation of its metabolite protoporphyrin IX (PpIX) in tumor cells. Under an operating microscope adapted with a specific blue emitting light source and filters, tumor tissue is visualized as red fluorescence. Tissue lacking sufficient PpIX concentrations appears blue. Because of its unique mechanism-of-action, GLEOLAN may allow neurosurgeons to see malignant tissue during surgery under blue light that they may not see under standard white light.

Glioma Pipeline Therapies

• Bristol-Myers Squibb

The Bristol-Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

• Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

• Orbus Therapeutics

Orbus Therapeutics Inc. is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company is focused and passionate about bringing a more positive outcome to patients facing life threatening or significantly life altering diseases.

• Eflornithine

Eflornithine, also known as a-diflurormethylornithine (DFMO), selectively targets and irreversibly inhibits ornithine decarboxylase (ODC), an enzyme essential for polyamine synthesis, and DNA and RNA function. Unlike multi-targeted tyrosine kinase inhibitors on the market or in development, eflornithine targets only one specific enzyme, ODC. In animal studies, eflornithine has been shown to inhibit the growth of malignant tumors, including intra cerebral mid- and high-grade gliomas. Eflornithine administration has also been shown to potentiate the anti-tumor activity of other chemotherapy agents. In single-arm and controlled, randomized clinical trials, eflornithine oral solution increased survival in patients with both newly diagnosed and recurrent anaplastic glioma. The primary and reversible side effects of eflornithine were diarrhea and hearing impairment.

• Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.

• DCVax-L

DCVax® is a platform technology that uses activated dendritic cells (the master cells of the immune system), and is designed to reinvigorate and educate the immune system to attack cancers. Unlike conventional cancer drugs, which use one active agent to hit one target on the cancer, DCVax uses many active agents to hit many targets on the cancer. For DCVax-L, the monocytes are differentiated into dendritic cells, and matured, activated and loaded with biomarkers (“antigens”) from the patient’s own tumor tissue (which is collected in a simple kit at the time of surgery to remove the tumor). The loading of biomarkers into the dendritic cells “educates” them about what the immune system needs to attack. The activated, educated dendritic cells are then isolated with very high purity and comprise the DCVax-L personalized vaccine. DCVax -L is administered to the patient through a simple intra-dermal injection in the upper arm, similar to a flu shot. The dendritic cells then convey the tumor biomarker information to the rest of the immune system agents (T cells, B cells and others), as “marching orders,” and the immune system agents then fan out through the body searching for anything with these biomarkers and attacking it.

• Medicenna Therapeutics

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer.

• MDNA55

MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2.

• Adastra Pharmaceuticals

Adastra Pharmaceuticals Inc. is an innovative, private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. The company’s vision is to identify, develop and deliver to patients important new therapies for diseases with significant unmet need. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

• Zotiraciclib

Zotiraciclib (TG02) is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas. As of January 2020, zotiraciclib is being evaluated by Adastra Pharmaceuticals in two separate Phase 1b clinical trials for the treatment of glioblastoma multiforme (GBM). Zotiracicib is also being developed as a potential treatment for diffuse intrinsic pontine glioma (DIPG), a rare pediatric cancer. Both forms of brain cancer are characterized by Myc overexpression. It is currently being investigated in Phase I/II clinical trial to treat patients with Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations.

• Onxeo

Onxeo is a French clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA-binding functions. The company’s therapeutic strategy focuses on fighting tumor resistance to treatments which poses ever-greater therapeutic challenges, further more so in aggressive or rare cancers. The approach is based upon unique mechanisms of action on DNA Damage Response and immune response and focuses on bringing first-in-class and disruptive compounds from translational research to proof-of-concept in man in cancer indications with high unmet needs.

• AsiDNA

A first-in-class product candidate in the leading field of DNA Damage Response (DDR), AsiDNA disrupts and exhausts the ability of tumor cells to repair their DNA by acting upstream of multiple repair pathways. AsiDNA and its technology originate from three major French academic centers: Curie Institute, CNRS, and the Museum of Natural History. It aims to offer new treatment options for patients suffering from various types of cancer. AsiDNA is a short double-stranded DNA fragment (oligonucleotide) that acts as a decoy, mimicking double-strand breaks in the DNA of the tumor cell. AsiDNA molecules trigger false DNA break signals to activate and attract DNA repair proteins, which prevents their recruitment to the site of actual DNA damage. As a result, damages to tumor cells’ DNA remain unrepaired.

Gain strategic intelligence on Glioma Emerging Therapies, pipeline highlights, and competitive trends shaping the Glioma market @ Glioma Preclinical and Discovery Stage Products

Glioma Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: Glioma Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Glioma Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Glioma Competitive Landscape Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Stay informed on the latest advancements in Glioma Research and development—Download the in-depth pipeline and competitive landscape report @ Glioma Market Drivers and Barriers

Scope of the Glioma Competitive Landscape Report

• Coverage- Global
• Glioma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac, and others.
• Glioma Therapies- DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide, and others.
• Glioma Marketed Therapies and Pipeline Therapies
• Glioma Preclinical and Discovery Stage Products, Unmet Needs

Understand the Glioma Companies, drugs, and market dynamics driving the Glioma Pipeline in 2025—Request your copy of the report now @ Glioma Mechanism of Action and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Glioma: Overview
4. Glioma -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Glioma: Company and Product Profiles (Marketed Therapies)
8. Novartis
9. Tafinlar + Mekinist
10. Glioma: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Bristol-Myers Squibb
13. Opdivo
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Medicenna Therapeutics
17. MDNA55
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I/II)
20. Onxeo
21. AsiDNA
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Evgen Pharma
25. SFX-01
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Glioma Unmet needs
29. Glioma Market drivers and barriers
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glioma-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioma Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s, “Antibody Drug Conjugate Competitive landscape, 2025,” report provides comprehensive insights about 180+ companies and 290+ drugs in Antibody Drug Conjugate Competitive landscape. It covers the Antibody Drug Conjugate therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ADC pipeline products in this space.

Explore the full insights into the evolving Antibody Drug Conjugate Pipeline and discover which companies are leading the innovation race @ Antibody Drug Conjugate Competitive Landscape Report

Key Takeaways from the Antibody Drug Conjugate Competitive Landscape Report

• On 22 August 2025, GlaxoSmithKline announced a study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether GSK5764227 makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether GSK576227 is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving GSK5764227 and the other receiving topotecan.
• On 20 August 2025, Alentis Therapeutics AG conducted a study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
• DelveInsight’s Antibody Drug Conjugate competitive landscape report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
• The leading Antibody Drug Conjugate Companies such as NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, and Navrogen, and others.
• Promising Antibody Drug Conjugate Pipeline Therapies such as Sacituzumab govitecan, STI-6129, Taxotere (docetaxel), DS-8201a, REGN5093-M114, Cemiplimab, Sacituzumab Govitecan-hziy, M9140, Talazoparib, LCB84 and others.

Unlock detailed analysis of the Antibody Drug Conjugate Competitive Landscape 2025 and identify key growth opportunities @ Antibody Drug Conjugate Research and Development Report

Antibody Drug Conjugate Marketed Therapies

• Pfizer

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. The strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people’s live.

• MYLOTARG

MYLOTARG is an antibody-drug conjugate (ADC) composed of the cytotoxic agent calicheamicin, attached to a monoclonal antibody (mAB) targeting CD33, an antigen expressed on the surface of myeloblasts in up to 90 percent of AML patients. When MYLOTARG binds to the CD33 antigen on the cell surface it is absorbed into the cell and calicheamicin is released causing cell death. MYLOTARG was approved by the U.S. Food and Drug Administration in September 2017 for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG originates from a collaboration between Pfizer and Celltech, now UCB. Pfizer has sole responsibility for all manufacturing, clinical development and commercialization activities for this molecule. Pfizer also collaborated with SFJ Pharmaceuticals Group on the registrational program for MYLOTARG.

• AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. Daiichi Sankyo Company, Limited and AstraZeneca entered into a global collaboration to jointly develop and commercialise Enhertu (a HER2-directed ADC) in March 2019, and datopotamab deruxtecan (DS-1062; a TROP2-directed ADC) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for manufacturing and supply of Enhertu and datopotamab deruxtecan. Building on the first approval of Enhertu, a HER2-directed ADC, in previously treated HER2-positive metastatic breast cancer, AstraZeneca and Daiichi Sankyo are exploring its potential in earlier lines of treatment and in new breast cancer settings.

• Enhertu

Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a (or one or more) prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial. Enhertu (5.4mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial. Enhertu (5.4mg/kg) is approved under accelerated approval in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumours have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Enhertu (6.4mg/kg) is approved in more than 30 countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial and/or DESTINY-Gastric02 trial.

Antibody Drug Conjugate Pipeline Therapies and Company

• Jiangsu Hengrui Medicine Co Ltd.

Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

• SHR-A1811

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells.

Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive breast cancer. The drug is also being evaluated for the treatment of gynaecological cancer, gastric cancer, non-small cell lung cancer, oesophageal cancer, and solid tumors.

• Seagen Inc.

Seagen, formerly Seattle Genetics, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas and CD30-expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology, which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.

• Ladiratuzumab Vedotin

Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics’ proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Unresectable Locally Advanced or Metastatic Solid Tumors.

• ImmunoGen, Inc.

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, ImmunoGen, Inc. aim to disrupt the progression of cancer and offer the patients more good days. ImmunoGen, Inc. believe ADCs have a promising and durable role in cancer care. This belief has driven the work for over four decades. It’s what has led to the leadership position in the ADC field, and it’s why everything ImmunoGen, Inc. do is about developing the most precise, targeted cancer therapies.

• IMGN151

IMGN151 is a next-generation Antibody-drug Conjugate designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). The investigational drug comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRα, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FRα expression and compared to IMGN853. In in vitro studies, both IMGN151 and mirvetuximab soravtansine had similar activity against FRα-high KB cells. However, IMGN151 was up to 200 times more active against four FRα-medium cell lines. Furthermore, IMGN151 had also notably stronger bystander killing activity in a mixed culture of target-positive and negative cells. In in vivo studies, IMGN151 induced complete tumor regressions of human tumor xenograft models with high (KB, H-score of 300), medium (Igrov-1 and Ishikawa, H-score of 140 and 100, respectively) and low (Ov-90, H-score of 30) FRα expression. All tested doses were well tolerated with no body weight loss observed. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Endometrial Cancer.

• Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging the world class science and technology for the purpose “to contribute to the enrichment of quality of life around the world.” In addition to the current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

• DS-6000

DS-6000 is an investigational potential first-in-class CDH6 directed ADC and one of five ADCs in clinical development in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Daiichi Sankyo is developing DS-6000 through a strategic collaboration with Sarah Cannon Research Institute with study operational oversight and delivery provided through Sarah Cannon’s early phase oncology clinical research organization, Sarah Cannon Development Innovationsin Nashville, TN. CDH6 (human cadherin-6) is a cadherin family protein overexpressed in several cancers, particularly ovarian tumors and renal cell carcinoma. Overexpression of CDH6 is associated with tumor growth and proliferation and is correlated with poor prognosis in patients with renal cell carcinoma. No CDH6 directed cancer therapies are currently approved for treatment of any cancer. Currently, the drug is in the Phase I stage of its development for the treatment of Solid tumors.

Gain strategic intelligence on Antibody Drug Conjugate Emerging Therapies, pipeline highlights, and competitive trends shaping the market @ Antibody Drug Conjugate Preclinical and Discovery Stage Products

Antibody Drug Conjugate: Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Antibody Drug Conjugate: Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate Competitive Landscape

The Antibody Drug Conjugate report comprises of comparative assessment of Antibody Drug Conjugate Companies (by therapy, development stage, and technology).

Antibody Drug Conjugate Report Assessment

• Antibody Drug Conjugate Company Analysis
• Antibody Drug Conjugate Therapeutic Assessment
• Antibody Drug Conjugate Pipeline Assessment
• Inactive Antibody Drug Conjugate drugs assessment
• Antibody Drug Conjugate Unmet Needs

Stay informed on the latest advancements in Antibody Drug Conjugate Research and development—Download the in-depth pipeline and competitive landscape report @ Antibody Drug Conjugate Market Drivers and Barriers

Scope of the Antibody Drug Conjugate Competitive Landscape Report

• Coverage- Global
• Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, and Navrogen, and others.
• Antibody Drug Conjugate Pipeline Therapies- Sacituzumab govitecan, STI-6129, Taxotere (docetaxel), DS-8201a, REGN5093-M114, Cemiplimab, Sacituzumab Govitecan-hziy, M9140, Talazoparib, LCB84 and others.
• Antibody Drug Conjugate Marketed Therapies and Pipeline Therapies
• Antibody Drug Conjugate Preclinical and Discovery Stage Products, Unmet Needs

Understand the Antibody Drug Conjugate Companies, drugs, and market dynamics driving the Antibody Drug Conjugate Pipeline in 2025—Request your copy of the report now @ Antibody Drug Conjugate Mechanism of Action and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Antibody Drug Conjugate Overview
4. Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
8. Pfizer
9. MYLOTARG
10. Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. ADC Therapeutics
13. Zynlonta
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Seagen Inc.
17. Ladiratuzumab Vedotin
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. ImmunoGen, Inc.
21. IMGN151
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Antibody Drug Conjugate – Unmet needs
29. Antibody Drug Conjugate– Market drivers and barriers
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/antibody-drug-conjugate-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Antibody Drug Conjugate Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s, “CAR T – Cell Therapy Competitive landscape, 2025,” report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the full insights into the evolving CAR-T Cell Therapy Pipeline and discover which companies are leading the innovation race @ CAR-T Cell Therapy Competitive Landscape Report

Key Takeaways from the CAR-T Cell Therapy Competitive Landscape Report

• On 20 August 2025, Juno Therapeutics Inc. announced a study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
• On 19 August 2025, Novartis Pharmaceuticals conducted a study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.
• DelveInsight’s CAR-T Cell Therapy competitive landscape report depicts a robust space with 250+ active players working to develop 500+ pipeline therapies for CAR-T Cell Therapy treatment.
• The leading CAR-T Cell Therapy Companies such as Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead Sciences, Miltenyi Biotec, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd., Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine and others.
• Promising CAR-T Cell Therapy Therapies such as Itacitinib, Cyclophosphamide, Fludarabine, CD7 CAR-T, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101 and others.

Unlock detailed analysis of the CAR-T Cell Therapy Competitive Landscape 2025 and identify key growth opportunities @ CAR-T Cell Therapy Research and Development Report

CAR T-Cell Therapy Marketed Therapies

• JW Therapeutics

JW Therapeutics is an innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and WuXi AppTec in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring the hope of a cure for Chinese and global patients, and to lead the healthy and standardized development of China’s cell immunotherapy industry.

• Relmacabtagene autoleucel

Relmacabtagene autoleucel injection (abbreviated as Relma-cel, trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Relma-cel was approved by the China National Medical Products Administration (NMPA) in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, making it the first CAR-T product approved as Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designations. Relma-cel is the first CAR-T product approved as a Category 1 biologics product in China, and sixth approved CAR-T product globally. Relma-cel, JW Therapeutics’ first CAR-T product, was independently developed based on a CAR T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company) to meet the needs of the Chinese market.

• Kite Pharma

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. The goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumors. Its industry-leading cell therapy technology uses the power of a person’s own immune system to target and attack their tumors. This is accomplished through the use of genetically modified T cells that can increase the number of tumor-specific T cells and strengthen the body’s ability to kill certain types of cancer cells.

• KTE-X19

KTE-X19 is an investigational, autologous, anti-CD19 CAR T cell therapy. KTE-X19 uses the XLP™ manufacturing process that includes T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is a necessary step in certain B-cell malignancies with evidence of circulating lymphoblasts. KTE-X19 is currently in Phase I/II trials in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).In December 2020, Kite, announced that the European Commission has granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. In July 2020, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

• Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.

• Abecma

Abecma recognizes and binds to BCMA on the surface of multiple myeloma cells leading to CAR T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells. Abecma is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb and 2seventy bio. The companies’ broad clinical development program for Abecma includes clinical studies (KarMMa-2, KarMMa-3, KarMMa-9) in earlier lines of treatment for patients with multiple myeloma. Abecma is the first and only CAR T cell therapy approved that is directed to recognize and bind to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells.

CAR T- Cell Pipeline Therapies and Companies

• CARsgen

CARsgen is a biopharmaceutical company with operations in China and the US and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The Company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors and reducing treatment costs. The Company’s vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

• Zevorcabtagene autoleucel

Zevor-cel (CT053) is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of R/R MM. CT053 uses a CAR construct with a fully human BCMA-specific single-chain variable fragment designed to have lower immunogenicity and increased stability. CARsgen is conducting a Phase I/II clinical trial to evaluate the safety and efficacy of zevor-cel for R/R Multiple myeloma. The Company also plans to conduct additional clinical trials to develop zevor-cel as an earlier line of treatment for multiple myeloma. CARsgen hopes the therapy will address challenges of T-cell exhaustion by reducing self-activation of CAR T-cells when tumor-associated targets are not present. The Company believes that zevor-cel is well positioned to potentially reshape the treatment paradigm for multiple myeloma and become a foundational treatment for multiple myeloma patients.

• Cartesian Therapeutics

Founded in 2016 and with three assets currently in clinical trials, Cartesian is the leader in mRNA-engineered cell therapy. Cartesian’s vision is to cure disease by mRNA engineering any cell, to deliver to any tissue, any combination of therapies. The company is pioneering mRNA cell therapies in and beyond oncology, with products in development for respiratory, autoimmune, and oncologic disorders. All investigational therapies are manufactured at Cartesian’s wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.

• Descartes 011

Descartes-11 is engineered with Cartesian’s RNA Armory℠ platform to express its CAR molecules transiently instead of permanently, thereby reducing both short-term and long-term risks inherent with conventional CAR T-cell therapies. Descartes-11 is manufactured in-house at Cartesian’s wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. A Phase 1 study of Descartes-11 in patients with advanced myeloma showed no evidence of typical CAR T-cell toxicities such as cytokine release syndrome (CRS) of neurotoxicity. Tens of billions of cells are mRNA-engineered with the CAR molecule so that the full therapeutic dose can be administered with each infusion. This eliminates the need for preconditioning chemotherapy required by conventional CAR T-cell therapies. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Multiple Myeloma.

• Autolus Therapeutics plc.

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

• AUTO8

AUTO8 is our next-generation product candidate for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. Company have developed an optimized BCMA CAR which is designed for improved killing of target cell that express BCMA at low levels. This has been combined with fast off rate CD19 CAR from obe-cel. Autolus Therapeutics believe that the design of AUTO8 has the potential to induce deep and durable responses and extend the durability of effect over other BCMA CARs currently in development.

• Sana Biotechnology

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.

• SG299

SG299 has the potential to generate CAR T cells in vivo (inside the patient), eliminating the need for conditioning chemotherapy and complex CAR T cell manufacturing. The company’s goal is to file an IND this year to study this drug candidate in patients with B cell malignancies. In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition. SG299 has at least a 50X improvement in product potency, which Sana believes has the potential to translate into better efficacy, safety, and long-term manufacturability. The company plans to use this second-generation process for the first-in-human studies in patients with B cell malignancies.

Gain strategic intelligence on CAR-T Cell Therapy Emerging Therapies, pipeline highlights, and competitive trends shaping the CAR-T Cell Therapy Market @ CAR-T Cell Therapy Preclinical and Discovery Stage Products

CAR T – Cell Therapy Analytical Perspective by DelveInsight

In-depth Commercial Assessment: CAR T – Cell Therapy Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

CAR T – Cell Therapy Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

CAR T- Cell Therapy Report Assessment

• CAR T-Cell Therapy Company Analysis
• CAR T-Cell Therapy Therapeutic Assessment
• CAR T- Cell Therapy Pipeline Assessment
• CAR T-Cell Therapy Inactive drugs assessment
• CAR T-Cell Therapy Unmet Needs

Stay informed on the latest advancements in CAR-T Cell Therapy Research and development—Download the in-depth pipeline and competitive landscape report @ CAR-T Cell Therapy Market Drivers and Barriers

Scope of the CAR-T Cell Therapy Pipeline Report

• Coverage- Global
• CAR-T Cell Therapy Companies- Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead Sciences, Miltenyi Biotec, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd., Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine and others.
• CAR-T Cell Therapy Therapies- Itacitinib, Cyclophosphamide, Fludarabine, CD7 CAR-T, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101 and others.
• CAR-T Cell Therapy Marketed Therapies and Pipeline Therapies
• CAR-T Cell Therapy Preclinical and Discovery Stage Products, Unmet Needs

Understand the CAR-T Cell Therapy Companies, drugs, and market dynamics driving the CAR-T Cell Therapy Pipeline in 2025—Request your copy of the report now @ CAR-T Cell Therapy Mechanism of Action and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. CAR T – Cell Therapy: Overview
4. CAR T – Cell Therapy-Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. CAR T – Cell Therapy: Company and Product Profiles (Marketed Therapies)
8. JW Therapeutics
9. Relmacabtagene autoleucel
10. Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Registered)
12. CARsgen
13. Zevorcabtagene autoleucel
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Cartesian Therapeutics
17. Descartes 011
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Autolus Therapeutics
21. AUTO-8
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Sana Biotechnology
25. SG299
26. Drug profiles in the detailed report…..
27. Inactive Products
28. CAR T – Cell Therapy – Unmet needs
29. CAR T – Cell Therapy– Market drivers and barriers
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Cell Therapy Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s “Bispecific antibody Competitive landscape, 2025,” report provides comprehensive insights about 180+ companies and 250+ drugs in the Bispecific antibody Competitive landscape. It covers the Bispecific Antibodies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive bispecific antibody pipeline products.

Explore the full insights into the evolving Bispecific Antibodies Pipeline and discover which companies are leading the innovation race @ Bispecific Antibodies Competitive Landscape Report

Key Takeaways from the Bispecific Antibodies Competitive Landscape Report

• On 21 August 2025, BioNTech SE announced a a Phase II, multisite, open-label, single arm study with two parts in participants with advanced/metastatic NSCLC which progressed after a first-line chemoimmunotherapy. Part 1 is safety run-in with BNT327 (Dose 1 or Dose 2) plus docetaxel and will include up to 12 participants to be treated in Part 1A and 1B sequentially. Part 2 is a dose expansion at the deemed safe dose of BNT327 plus docetaxel.
• On 21 August 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called “relapsed”), or did not respond to treatment (called “refractory”). FL and MZL are subtypes of Non-Hodgkin’s lymphoma (NHL).
• DelveInsight’s Bispecific Antibodies competitive landscape report depicts a robust space with 180+ active players working to develop 250+ pipeline therapies for Bispecific Antibodies treatment.
• The leading Bispecific Antibodies Companies such as Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim and others.
• Promising Bispecific Antibodies Pipeline Therapies such as Elranatamab, Mosunetuzumab, Glofitamab, Obinutuzumab, AK112, MCLA-158, AZD2936, AK104, Zanidatamab, Docetaxel, Tislelizumab and others.

Unlock detailed analysis of the Bispecific Antibodies Competitive Landscape 2025 and identify key growth opportunities @ Bispecific Antibodies Research and Development Report

Bispecific Antibody Marketed Therapies Company

• Janssen

Janssen is creating a future where disease is a thing of the past. Janssen is the Pharmaceutical company of Johnson & Johnson, working to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. The company focuses on areas of medicine where they can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

• Amivantamab

Amivantamab is a fully human bispecific antibody that targets EGFR and MET, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to create Amivantamab was selected in collaboration between Genmab and Janssen. Subsequent development work was carried out by Janssen. In 2021, Janssen received approval from the U.S. FDA for amivantamab-vmjw (RYBREVANT®) for the treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. This is the first regulatory approval for a therapy that was created using Genmab’s proprietary DuoBody bispecific technology platform.

• Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen is one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen Therapeutics has changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and vital medicines.

• Blinatumomab

Blinatumomab (AMG 103) is a bispecific T cell engager (BiTE®) antibody designed to direct the body’s cell-destroying T cells against target cells expressing CD19, a protein found on the surface of B-cell lymphomas and leukemias. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells to cancer cells. Blinatumomab is the first of the BiTE antibodies and Amgen has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and indolent B cell lymphoma and from the European Medicines Agency for the treatment of indolent B cell lymphoma, ALL, CLL and mantle cell leukemia (MCL). The drug is approved for the treatment of Precursor B-cell lymphoblastic leukaemia-lymphoma. The drug is currently being evaluated for the treatment of Non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, and others.

Bispecific Antibody Pipeline Therapies Company and Product Profiles

• AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in these therapy areas – Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Diseases.

• Gefurulimab

Gefurulimab is an investigational, humanized bispecific VHH antibody directed against terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory activities. Upon administration, gefurulimab, with its anti-C5 antibody moiety, targets and binds to terminal complement protein C5, thereby blocking the terminal complement pathway of complement activation. This inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases and leads to tissue destruction. The binding of gefurulimab to albumin, with its albumin binding domain, increases its half-life.

• Sichuan Baili Pharmaceutical

Sichuan Baili is a biopharmaceutical company focusing on the research and development, manufacturing, and commercialization of medicines for cancer and other diseases. With strong R&D teams in both China and US, it has developed fully integrated proprietary platforms in bispecific, multi-specific antibodies and antibody-drug conjugates. Its highly differentiated platforms have generated a pipeline of six clinical stage anti-cancer drug candidates. The Company also has state-of-the-art manufacturing capability designed and built to meet cGMP standards. It is a buyer of pharmaceutical products and has business partners. The company has not made any global approval of a PD-L1/4-1BB bispecific antibody for patients with pancreatic cancer. Sichuan Baili Tianheng Pharmaceutical, a subsidiary of Sichuan Baili Pharmaceutical, develops and manufactures small molecules as well as immunologicals. The products are of various therapeutic categories including anti-inflammatory, antiphlogistics, urology, gynecology, obstetrics, immunological preparations, and others. The primary business model of Sichuan Baili Tianheng Pharmaceutical is healthcare funding and investors.

• SI-B001

SI-B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and the activation of its downstream signal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, and down-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy. The drug is in phase III stage of its clinical trial.

• Innovent Biologics

Innovent Biologics is a global biopharmaceutical company established in 2011, focusing on the development, manufacturing, and commercialization of innovative medicines, particularly in the areas of cancer, autoimmune, cardiovascular, and metabolic diseases. The company is headquartered in Suzhou, Jiangsu, China, and has a presence in the United States, with a lab located in Rockville, Maryland. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), and Pemazyre® (Pemigatinib Oral Inhibitor). The company’s pipeline consists of 36 high-quality assets, with 2 under NMPA NDA review, 5 in Phase III or pivotal clinical trials, and 19 more in early clinical stages. Innovent has entered into more than 30 strategic collaborations with international partners, including Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center. The company’s mission is to discover and develop high-quality biopharmaceutical products that are affordable and accessible to ordinary people.

• IBI322

IBI322 is a recombinant anti-human CD47/PD-L1 bispecific antibody developed by Innovent Biologics. As a bispecific antibody, IBI322 targets CD47 on the surface of tumor cells, blocks SIRPα/CD47 pathway and activates macrophages to attack the tumor cells. Furthermore, IBI322 target PD-L1 on the surface of tumor cells, blocks the PD-1/PD-L1 pathway, which counteracts the inhibition of T cells and activates the T cells to attack the tumor cells. By inhibiting two different targets, IBI322 can not only activate both innate immune pathway and adaptive immune pathway, which provides synergistic effect, but also reduce the red blood cell destruction. IBI322 is currently being evaluated in Phase II for the treatment of Hematological malignancies and Solid tumors.

• IGM Biosciences

IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets.

• Imvotamab

Imvotamab is a novel IgM-based CD20 x CD3 bispecific antibody T cell engager (TCE) with the therapeutic potential to be a backbone treatment in hematology. Preclinical research demonstrates that imvotamab may have advantages over IgG bispecific antibodies including greater binding power to CD20 expressing cancer cells especially when CD20 expression has been reduced due to prior treatment with anti-CD20 antibodies. It has also been shown to have good target cell killing efficacy combined with a lower cytokine release profile associated with the T cell directed cellular cytotoxicity (TDCC) mechanism. Data generated from Phase 1 clinical trials provide evidence that imvotamab exhibits a favorable safety and tolerability profile with promising activity in refractory or relapsed Non-Hodgkin Lymphoma patients. Imvotamab is currently being studied in two Phase II trials to assess the safety and efficacy of two doses 100 mg and 300 mg, in patients with diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).

• MacroGenics

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

• MGD024

MGD024 is an investigational, next-generation, bispecific CD123 × CD3 DART® molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML). MGD024 was designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life. In December 2021, the company presented preclinical MGD024 data at the American Society of Hematology (ASH) Annual Meeting that showed the potential for anti-tumor activity from the combination of MGD024 with standard of care agents used to treat AML. MacroGenics initiated a Phase I study of MG024 in patients with hematologic malignancies in 2022. In October 2022, MacroGenics announced that it had entered into an exclusive option and collaboration agreement with Gilead to develop MGD024 and two additional bispecific research programs. MacroGenics is responsible for the ongoing Phase I study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points.

Gain strategic intelligence on Bispecific Antibodies Emerging Therapies, pipeline highlights, and competitive trends shaping the market @ Bispecific Antibodies Preclinical and Discovery Stage Products

Bispecific antibody Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Bispecific antibody Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Bispecific antibody Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Bispecific antibody Report Assessment

• Company Analysis
• Bispecific Antibodies Therapeutic Assessment
• Bispecific Antibodies Pipeline Assessment
• Inactive drugs assessment
• Bispecific Antibodies Unmet Needs

Stay informed on the latest advancements in Bispecific Antibodies research and development—Download the in-depth pipeline and competitive landscape report @ Bispecific Antibodies Market Drivers and Barriers

Scope of the Bispecific Antibodies Pipeline Report

• Coverage- Global
• Bispecific Antibodies Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim and others.
• Bispecific Antibodies Pipeline Therapies- Elranatamab, Mosunetuzumab, Glofitamab, Obinutuzumab, AK112, MCLA-158, AZD2936, AK104, Zanidatamab, Docetaxel, Tislelizumab and others.
• Bispecific Antibodies Marketed Therapies and Pipeline Therapies
• Bispecific Antibodies Preclinical and Discovery Stage Products, Unmet Needs

Understand the Bispecific Antibodies companies, drugs, and market dynamics driving the Bispecific Antibodies Pipeline in 2025—Request your copy of the report now @ Bispecific Antibodies Mechanism of Action and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Bispecific antibodies: Overview
4. Bispecific antibodies -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Bispecific antibodies: Company and Product Profiles (Marketed Therapies)
8. Johnson & Johnson Innovative Medicine
9. Amivantamab
10. Bispecific antibodies: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. AstraZeneca
13. Gefurulimab
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. IGM Biosciences
17. Imvotamab
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. MacroGenics
21. MGD024
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Bispecific antibodies- Unmet needs
29. Bispecific antibodies – Market drivers and barriers
30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bispecific Antibodies Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s, “Cancer Vaccines Competitive landscape 2025” report provides comprehensive insights about 250+ companies and 300+ drugs in Cancer Vaccines Competitive landscape. It covers the Cancer Vaccines therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the full insights into the evolving Cancer Vaccines Pipeline and discover which companies are leading the innovation race @ Cancer Vaccines Competitive Landscape Report

Key Takeaways from the Cancer Vaccines Pipeline Report

• On 24 August 2025, Columbia University announced a study of the 9vHPV vaccine among a population of children, adolescents, and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini.
• DelveInsight’s Cancer Vaccines competitive landscape report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Cancer Vaccines treatment.
• The leading Cancer Vaccines Companies such as Imvax, Transgene, BrightPath Biotherapeutics, Vaccitech, Amal Therapeutics, Enterome, Moderna, Inc., Ultimovacs ASA OSE Immunotherapeutic, IO Biotech, PDS Biotech, LIKANGLIFE SCIENCES, ISA Pharmaceuticals Voltron Therapeutics, Inc., RNAImmune, and others.
• Promising Cancer Vaccines Therapies such as GX-188E, ACIT-1, V503, VGX 3100, GSK 1437173A, Gardasil ® 9, Cervarix™, RV001V, CDX-1401, 9vHPV Vaccine, Pembrolizumab and others.

Unlock detailed analysis of the Cancer Vaccines Competitive Landscape 2025 and identify key growth opportunities @ Cancer Vaccines Research and Development Report

Cancer Vaccines Marketed Therapies

• Dendreon Corporation

Dendreon is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of the patient’s own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Dendreon’s name derives from the “”Dendritic Cell”” which forms a major component of the company’s product candidates that use the “”Dendreon Cassette Technology”” to insert a disease-specific target protein into a general platform. Dendreon believes its process can be optimized and generalized to other diseases by exchanging the PAP component of Provenge with better targets specific to different diseased cells.

• Provenge

Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the US Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic Metastatic Hormone-Refractory Prostate Cancer (HRPC).

• Merck & Co., Inc.

Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of its mission to save and improve lives. The company continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – and aspires to be the premier research-intensive biopharmaceutical company in the world.

• H101

HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11. While it is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

Cancer Vaccines Pipeline Therapies and Company

• OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile. Tedopi (innovative combination of neoepitopes) is the the company’s most advanced product.

• Tedopi

Tedopi (formerly known as OSE-2101), is a cancer vaccine being developed by OSE Immunotherapeutics for the treatment of certain types of lung cancer. It contains a combination of 10 optimized neo-epitopes, which are parts of proteins that structurally alter cancer cells and trigger strong immune responses against them. The epitopes present in Tedopi are optimized from five tumorous antigens. The epitopes express a minimum of one of the tumor antigens and generate a specific response from cytotoxic (aka killer) T-cells against cancer cells. Tedopi works by stimulating killer T-cells, enabling them to spot and eliminate cancerous cells, which is a key process in the treatment of disease. Tedopi has been granted orphan drug designation by the US Food and Drug Administration (FDA) and is recognized as a personalized medicine for the treatment of HLA-A2 positive NSCLC patients in Europe.

• IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark.

• IO102-IO103

IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1. The combination is currently investigated in Phase III trial for Melanoma and in Phase I/II for some other cancers. IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on IO Biotech’s proprietary T-win® technology platform which enables the identification of compounds with a dual mechanism of action targeting and directly killing immunosuppressive cells and tumor cells while indirectly activating other T-effectors, leading to strong anti-tumor responses without adding additional safety concern. Specifically, IO102 and IO103 are first-in-class, immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells.

• PDS Biotech

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

• PDS0101

PDS0101 is a novel investigational human papilloma virus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. PDS0101 is given by a simple subcutaneous injection in combination with other immunotherapies and cancer treatments. Interim data suggests PDS0101 generates clinically effective immune responses, and the combination of PDS0101 with other treatments demonstrates significant disease control by shrinking tumors, delaying disease progression and/or prolonging survival. The combination of PDS0101 with other treatments does not appear to compound the toxicity of other agents. PDS0101 is currently being evaluated in four Phase 2 clinical trials for the treatment of various types of HPV-positive cancers.

Gain strategic intelligence on Cancer Vaccines Emerging Therapies, pipeline highlights, and competitive trends shaping the Cancer Vaccines market @ Cancer Vaccines Preclinical and Discovery Stage Products

Cancer Vaccines Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Cancer Vaccines Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Cancer Vaccines Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Cancer Vaccines Competitive Landscape Report Assessment

• Cancer Vaccines Company Analysis
• Cancer Vaccines Therapeutic Assessment
• Cancer Vaccines Pipeline Assessment
• Cancer Vaccines Inactive drugs assessment
• Cancer Vaccines Unmet Needs

Stay informed on the latest advancements in Cancer Vaccines research and development—Download the in-depth pipeline and competitive landscape report @ Cancer Vaccines Market Drivers and Barriers

Scope of the Cancer Vaccines Market Report

• Coverage- Global
• Cancer Vaccines Companies- Imvax, Transgene, BrightPath Biotherapeutics, Vaccitech, Amal Therapeutics, Enterome, Moderna, Inc., Ultimovacs ASA OSE Immunotherapeutic, IO Biotech, PDS Biotech, LIKANGLIFE SCIENCES, ISA Pharmaceuticals Voltron Therapeutics, Inc., RNAImmune, and others.
• Cancer Vaccines Therapies- GX-188E, ACIT-1, V503, VGX 3100, GSK 1437173A, Gardasil ® 9, Cervarix™, RV001V, CDX-1401, 9vHPV Vaccine, Pembrolizumab and others.
• Cancer Vaccines Marketed Therapies and Pipeline Therapies
• Cancer Vaccines Preclinical and Discovery Stage Products, Unmet Needs

Understand the Cancer Vaccines Companies, drugs, and market dynamics driving the Cancer Vaccines Pipeline in 2025—Request your copy of the report now @ Cancer Vaccines Mechanism of Action and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Cancer Vaccines: Overview
4. Cancer Vaccines -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Cancer Vaccines: Company and Product Profiles (Marketed Therapies)
8. Dendreon Corporation
9. Provenge
10. Cancer Vaccines: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. OSE Immunotherapeutics
13. Tedopi
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Company Name
17. Product Name
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Company Name
21. Drug Name
22. Preclinical and Discovery Stage Products
23. Company Name
24. Product Name
25. Inactive Products
26. Cancer Vaccines- Unmet needs
27. Cancer Vaccines – Market drivers and barriers
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cancer-vaccines-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cancer Vaccines Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook